Close X
Attorney Spotlight

Find out which two countries Cheryl Palmeri gets the most questions about related to International Trade in today's market? Find out more>


Close X


Search our Experience

Experience Spotlight

In June 2016, AmSurg Corp. and Envision Healthcare Holdings, Inc. (Envision) announced they have signed a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction. Upon completion of the merger, which is expected to be tax-free to the shareholders of both organizations, the combined company will be named Envision Healthcare Corporation and co-headquartered in Nashville, Tennessee and Greenwood Village, Colorado. The company's common stock is expected to trade on the New York Stock Exchange under the ticker symbol: EVHC. Bass, Berry & Sims served as lead counsel on the transaction, led by Jim Jenkins. Read more.

AmSurg logo

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Inside the FCA blogInside the FCA blog features ongoing updates related to the False Claims Act (FCA), including insight on the latest legal decisions, regulatory developments and FCA settlements. The blog provides timely updates for corporate boards, directors, compliance managers, general counsel and other parties interested in the organizational impact and legal developments stemming from issues potentially giving rise to FCA liability.

Read More >

Janelle Waack Comments on Exclusivity Terms for Biologic Drugs in Trans-Pacific Partnership Agreement

Media Mentions

October 6, 2015

Bass, Berry & Sims attorney Janelle Waack provided comment for a Modern Healthcare article outlining the details of the Trans-Pacific Partnership Agreement, a trade agreement between the U.S. and 11 countries. As part of the agreement, countries will extend data exclusivity for biologic medicines for five to eight years instead of the 12 years that the United States and the pharmaceutical industry recommended. The trade agreement next goes to the U.S. Congress, who will need to vote whether to accept the deal. As Janelle points out in the article, Congress will need to "carefully consider the impact on the pharmaceutical industry and smaller companies that are doing the ground level research, saying the agreement raises questions about whether they would continue 'to pursue these lines of research in view of what could be a more limited period of exclusivity.'"

The full article, "Trade Deal Disappoints Drugmakers, Consumer Groups," was published by Modern Healthcare on October 5, 2015 and is available online.

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.